Denali Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Denali Therapeutics Inc
Current Price
$18.62
-3.97%Profile
Valuation (TTM)
Market Cap$2.95B
P/E-5.81
EV—
P/B2.91
Shares Out158.59M
P/Sales—
Revenue$0.00
EV/EBITDA—
Denali Therapeutics Inc (DNLI) Stock Analysis
Market Cap$2.95B
Current Price$18.62
P/E Ratio-5.81
Forward P/E—
PEG Ratio0.50
EPS$-2.97
Book Value$6.39
P/B Ratio2.91
DNLI Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 173M
Revenue
27M
FY19
336M
FY20
49M
FY21
108M
FY22
331M
FY23
—
FY24
—
FY25
Net Income
—
FY19
71M
FY20
—
FY21
—
FY22
—
FY23
—
FY24
—
FY25
DNLI 52-Week Range
$12.75
$22.74
50-Day MA: $19.92200-Day MA: $17.72
Did you know?
Price sits at 59% of its 52-week range.
Denali Therapeutics Inc (DNLI) Financial Summary
Denali Therapeutics Inc (DNLI) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $18.62 with a market capitalization of $2.95B.
Key valuation metrics include a P/E ratio of -5.81, price-to-book ratio of 2.91, and EPS of $-2.97. and return on equity of -50.1%.
DNLI Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $2.95B |
| P/E Ratio | -5.81 |
| EPS | $-2.97 |
| P/B Ratio | 2.91 |
| Return on Equity | -50.1% |
| Debt/Equity | 0.03 |
DNLI Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $26.68M | $-197.61M |
| FY20 | $335.66M | $71.14M |
| FY21 | $48.66M | $-290.58M |
| FY22 | $108.46M | $-325.99M |
| FY23 | $330.53M | $-145.22M |
| FY24 | $0.00 | $-422.77M |
| FY25 | $0.00 | $-512.54M |
About Denali Therapeutics Inc
Denali Therapeutics Inc
DNLI Free Cash Flow
Denali Therapeutics Inc generated $-422.10M in trailing twelve-month free cash flow, representing an FCF yield of -14.29%. This low FCF yield may reflect heavy reinvestment or growth spending.
DNLI Shares Outstanding
Denali Therapeutics Inc has 0.16 billion shares outstanding at a share price of $18.62, giving it a market capitalization of $2.95B.